Nanobiotix Operational and Financial Overview
Nanobiotix is making substantial strides in its strategic initiatives aimed at enhancing treatment opportunities for cancer patients. The company recently delivered updates regarding its operational achievements and financial stability in a report covering the third quarter of 2025. Key developments highlight a reinforced financial foundation and exciting progress in clinical programs that promise transformative results.
Financial Milestones for Sustainable Growth
In a significant achievement, Nanobiotix secured a non-dilutive royalty financing deal with HealthCare Royalty (HCRx) valued at up to $71 million. This milestone includes an initial payment of $50 million upon closing, with an additional $21 million anticipated within a year, contingent on certain performance metrics. This strong financial backing is essential for Nanobiotix as it aims for self-sufficiency in its long-term growth strategy.
Clinical Advancements in JNJ-1900 (NBTXR3)
Among the highlights of the operational update is the advancement of Nanobiotix’s JNJ-1900 (NBTXR3) program. Encouraging results from a Phase 1 study in esophageal cancer, conducted at The University of Texas MD Anderson Cancer Center, were presented at a notable medical conference. This success paves the way for future studies and potential new indications of JNJ-1900.
Phase 3 Sponsorship Transfer Completion
An important component of the report addressed the transfer of sponsorship responsibility of the NANORAY-312 study to Johnson & Johnson. This Phase 3 trial focuses on treating patients with locally advanced head and neck cancers, enhancing operational efficiencies as Johnson & Johnson takes over the major regulatory and operational efforts.
Update on Curadigm Nanoprimer Program
The Curadigm Nanoprimer initiative is another crucial driver for Nanobiotix's growth. Recently, the company filed new patent applications aimed at broadening its intellectual property scope and supporting a robust internal pipeline of Nanoprimer-based therapies. As collaborations on this innovative approach move forward, they indicate promising potential for breakthrough therapies in oncology.
Financial Health and Future Outlook
As of the end of September 2025, Nanobiotix reported €20.4 million in cash and cash equivalents. With the initial funding from the HCRx agreement, it is projected that the company will have sufficient resources to extend its operational runway into early 2028. This visibility into future cash flow will allow Nanobiotix to focus more squarely on its strategic objectives without immediate financial constraints.
Future Clinical Data Releases
Looking ahead to 2026, Nanobiotix expects to provide further updates from its ongoing research efforts. This includes final data from significant studies evaluating JNJ-1900 combined with checkpoint inhibitors for patients with advanced melanoma, as well as updates from various studies regarding lung and pancreatic cancers. The anticipated clinical data will play a critical role in shaping the future trajectory of the company’s research and development pathways.
About Nanobiotix
Founded in 2003, Nanobiotix is at the forefront of developing innovative cancer therapies, utilizing physics-based approaches to generate new treatment possibilities. The company’s commitment to pushing the boundaries of medical science aims to enhance the quality of life for patients facing cancer. Operating from its headquarters in Paris, France, Nanobiotix is publicly traded on both Euronext Paris and the Nasdaq Global Select Market.
Company Contact Information
Communications Department
Brandon Owens
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com
Investor Relations Department
Joanne Choi
VP, Investor Relations (US)
+1 (713) 609-3150
joanne.choi@nanobiotix.com
Ricky Bhajun
Director, Investor Relations (EU)
+33 (0) 79 97 29 99
investors@nanobiotix.com
Frequently Asked Questions
What financial milestones has Nanobiotix achieved recently?
Nanobiotix successfully closed a non-dilutive royalty financing deal worth up to $71 million, including an immediate payment of $50 million.
What progress has been made in the clinical trials of JNJ-1900?
The company advanced its JNJ-1900 program, with the first data from a Phase 1 study in esophageal cancer showing promising results.
What is the focus of Nanobiotix's Curadigm Nanoprimer program?
The Curadigm Nanoprimer program aims to develop new cancer therapies, expanding the company's intellectual property portfolio with new patents filed.
How is Nanobiotix ensuring its financial health?
With cash reserves of €20.4 million and expected earnings from their HCRx agreement, they have operational visibility into early 2028.
Where is Nanobiotix headquartered?
Nanobiotix is headquartered in Paris, France, and also operates in Cambridge, Massachusetts.
